EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Limited Visibility and Perception of the Clinical Relevance of Clopidogrel Pharmacogenetics in Cardiology Literature

Cinzia Dello Russo iD, Luigi Venetucci iD, Abisope Akintola iD, Dimitri Gagliardi iD, Ronnie Ramlogan, Munir Pirmohamed iD

Clinical and Translational Science · 2026-05 · 19 (5)

DOI: 10.1111/cts.70584 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Translational Science, online erschienen am 11.05.2026. Verfasst von Cinzia Dello Russo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK. Hauptthemen laut MEDLINE: Clopidogrel, Platelet Aggregation Inhibitors, Pharmacogenetics, Cardiology. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clopidogrel is an antiplatelet agent widely utilized in cardiology. It is a prodrug activated in the liver by the cytochrome P450 isoform CYP2C19. Variability in the CYPC2C19 gene influences the activation and efficacy of clopidogrel. This is covered in guidelines from the Clinical Pharmacogenetics Implementation Consortium, the Dutch Pharmacogenetics Working Group, and more recently the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics. Despite this extensive guidance, pharmacogenetic information is rarely used to guide clopidogrel prescription in cardiology patients. The present study assesses the visibility of the pharmacogenetic guidelines in the cardiology literature. We analyzed citations of the clopidogrel pharmacogenetic guidelines in the cardiology literature and in the cardiology guidelines/position statements on the treatment of acute coronary syndromes and stable coronary artery disease. Citations of these guidelines were found to be limited in the cardiology literature. Only 3 out of 19 cardiology guidelines/position statements refer to the pharmacogenetic guidelines. 58% of the cardiology guidelines/position statements mention clopidogrel pharmacogenetics but suggest that the use of pre‐emptive genotyping for CYP2C19 variants to guide clopidogrel prescription is of limited clinical relevance. Genetically determined variation in clopidogrel efficacy has poor visibility in the cardiology literature and clinical guidelines. It is perceived to have limited benefits for clinical practice despite mounting evidence from randomized controlled trials and systematic reviews/meta‐analyses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ClopidogrelPlatelet Aggregation InhibitorsPharmacogeneticsCardiologyAcute Coronary SyndromeCoronary Artery DiseaseHumansCytochrome P-450 CYP2C19Practice Guidelines as TopicPharmacogenomic VariantsPharmacogenomic Testing

Stichwörter der Autor:innen

CPIC guidelinesCYP2C19DPWG guidelinesUK CERSI‐PGx guidelinescardiovascular diseasesclopidogrelpharmacogenetics

Substanzen

ClopidogrelCytochrome P-450 CYP2C19Platelet Aggregation InhibitorsCYP2C19 protein, human

Autor:innen und Institutionen

  • Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.
  • Department of Translational Medicine and Surgery, Section of Pharmacology, Università Cattolica del Sacro Cuore - Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
  • Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
  • Manchester Institute of Innovation Research, Alliance Manchester Business School, The University of Manchester, Manchester, UK.
  • The Wolfson Centre for Personalised Medicine, Centre for Drug Safety Science, University of Liverpool, Liverpool, UK.

ORCID-Profile: Cinzia Dello Russo, Luigi Venetucci, Abisope Akintola, Dimitri Gagliardi, Munir Pirmohamed

Zitieren

APA

Dello Russo, C., Venetucci, L., Akintola, A., Gagliardi, D., Ramlogan, R., & Pirmohamed, M. (2026). Limited Visibility and Perception of the Clinical Relevance of Clopidogrel Pharmacogenetics in Cardiology Literature. Clinical and Translational Science, 19(5). https://doi.org/10.1111/cts.70584

Vancouver

Dello Russo C, Venetucci L, Akintola A, Gagliardi D, Ramlogan R, Pirmohamed M. Limited Visibility and Perception of the Clinical Relevance of Clopidogrel Pharmacogenetics in Cardiology Literature. Clinical and Translational Science. 2026;19(5). doi:10.1111/cts.70584

BibTeX
@article{DelloRusso2026,
  author = {Dello Russo, Cinzia and Venetucci, Luigi and Akintola, Abisope and Gagliardi, Dimitri and Ramlogan, Ronnie and Pirmohamed, Munir},
  title = {Limited Visibility and Perception of the Clinical Relevance of Clopidogrel Pharmacogenetics in Cardiology Literature},
  journal = {Clinical and Translational Science},
  year = {2026},
  volume = {19},
  number = {5},
  doi = {10.1111/cts.70584}
}
Kostenlos starten →